Novak Alfred J 4

What Happened

• Alfred J. Novak, a director of Pasithea Therapeutics Corp. (KTTA), received a derivative award on May 1, 2026 covering 152,783 shares. The filing lists the transaction as an award/grant (code A) with a reported price of $0.00. The instrument is described in the filing as an "Option" under the Issuer's 2023 Stock Incentive Plan.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (appears timely — within the standard two business-day reporting window).
• Shares/units granted: 152,783 (derivative award; reported price $0.00).
• Shares owned after transaction: not stated in the provided excerpt of the filing.
• Footnote: the Option vests in full on the one-year anniversary of the grant if Novak remains a director; the shares will fully vest upon a Change in Control (per the 2023 Stock Incentive Plan).
• Transaction code: A = Award/Grant (derivative), not an open-market purchase or sale.

Context

• This was a grant of an option-like award, not an immediate stock purchase. Until the award vests and any option is exercised (if applicable), Novak does not have freely tradable common shares from this grant.
• The filing does not report an intrinsic dollar value; the economic value depends on KTTA’s market price and any exercise terms. The vesting condition (one-year service or acceleration on change in control) is typical for director incentive grants.